BeiGene
BGNE
#958
Rank
โ‚น1.728 T
Marketcap
โ‚น15,795
Share price
0.49%
Change (1 day)
18.97%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -โ‚น1,366

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -โ‚น1,423. In 2022 the company made an earnings per share (EPS) of -โ‚น1,656 a decrease over its 2021 EPS that were of -โ‚น1,301.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น1,366-17.56%
2022-โ‚น1,65627.35%
2021-โ‚น1,301-19.96%
2020-โ‚น1,62520.81%
2019-โ‚น1,34531.52%
2018-โ‚น1,023417.57%
2017-โ‚น197.61-37.16%
2016-โ‚น314.48158.95%
2015-โ‚น121.45

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น85.51-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.09-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA